With some of the world’s wealthiest countries continuing to oppose temporary patent waivers for Covid-19 vaccines in order to more rapidly deploy life-saving shots worldwide, pharmaceutical giants Pfizer and Moderna have raised the price for European Union orders.
In its new supply contract with the E.U., Pfizer named a price of more than $23 per dose, up nearly 25% from about $18 on earlier purchases. Moderna said in its latest agreement that its mRNA vaccine will cost one-tenth more than its previous price, charging $25.50 per dose.
The two companies plan to provide the E.U. with 2.1 billion vaccine doses until 2023, and are already expected to rake in tens of billions of dollars this year from vaccine sales.
“Capitalism never fails to not surprise,” tweeted The New Yorker writer John Cassidy in response to reporting from the Financial Times.
With patent protections kept in place by the World Trade Organization (WTO) as E.U. countries including Germany, Switzerland, and the United Kingdom oppose lifting Trade-Related Aspects of Intellectual Property Rights (TRIPS) for Covid-19-related products, vaccine doses have mainly been available in wealthy countries.
According to the New York Times‘ latest analysis, 0.3% of doses have been administered in low-income countries, leading public health experts to warn that Covid-19 will continue to mutate and dangerous, highly infectious variants like Delta will continue to emerge and spread throughout the world.
The companies are raising their prices “just in time for the Delta variant,” one observer wrote on Twitter.
Pfizer and Moderna have raised their prices as Europe faces supply chain issues with the Johnson & Johnson and AstraZeneca vaccines — the latter of which has been more widely available in low-income countries — and as new studies showed higher efficacy of the mRNA vaccines compared to the cheaper shots.
An official involved in the price negotiations told the Financial Times that Pfizer and Moderna used the “usual pharma rhetoric” in discussing the price hikes.
“Vaccines work so they increased the ‘value,'” the official said.
With the two companies continuing to sell most of its supply to high-income countries, Pfizer’s sales are now expected to reach $56 billion and Moderna’s are expected to reach $30 billion.
“E.U., care to rethink your position on a patent waiver?,” tweeted Nick Dearden, director of Global Justice Now, which has been calling for the WTO to lift patent protections for Covid-19 vaccines for months.
Intellectual property lawyer Tahir Amin wrote on social media that lifting patent protections for vaccines, as South African and Indian WTO representatives first proposed last year, would suspend the tool “that enables and supports this monopoly” controlled by Big Pharma.
Yet the EU/UK and others continue to block a #TRIPSwaiver waiver that would suspend the very tool, IP, that enables and supports this monopoly.
Our Govts are complicit in this heist by pharma and companies across the board in other sectors. It’s the system they helped create. https://t.co/hoNryp86hg
— Tahir Amin (@realtahiramin) August 1, 2021
“Our governments are complicit in this heist by pharma and companies across the board in other sectors,” Amin said.
We’re not backing down in the face of Trump’s threats.
As Donald Trump is inaugurated a second time, independent media organizations are faced with urgent mandates: Tell the truth more loudly than ever before. Do that work even as our standard modes of distribution (such as social media platforms) are being manipulated and curtailed by forces of fascist repression and ruthless capitalism. Do that work even as journalism and journalists face targeted attacks, including from the government itself. And do that work in community, never forgetting that we’re not shouting into a faceless void – we’re reaching out to real people amid a life-threatening political climate.
Our task is formidable, and it requires us to ground ourselves in our principles, remind ourselves of our utility, dig in and commit.
As a dizzying number of corporate news organizations – either through need or greed – rush to implement new ways to further monetize their content, and others acquiesce to Trump’s wishes, now is a time for movement media-makers to double down on community-first models.
At Truthout, we are reaffirming our commitments on this front: We won’t run ads or have a paywall because we believe that everyone should have access to information, and that access should exist without barriers and free of distractions from craven corporate interests. We recognize the implications for democracy when information-seekers click a link only to find the article trapped behind a paywall or buried on a page with dozens of invasive ads. The laws of capitalism dictate an unending increase in monetization, and much of the media simply follows those laws. Truthout and many of our peers are dedicating ourselves to following other paths – a commitment which feels vital in a moment when corporations are evermore overtly embedded in government.
Over 80 percent of Truthout‘s funding comes from small individual donations from our community of readers, and the remaining 20 percent comes from a handful of social justice-oriented foundations. Over a third of our total budget is supported by recurring monthly donors, many of whom give because they want to help us keep Truthout barrier-free for everyone.
You can help by giving today. Whether you can make a small monthly donation or a larger gift, Truthout only works with your support.